Development · 6 Oct 2026
1 publisher has reported this development. Each act of reporting is below, cited.
Eyestem Research presented interim results from its Phase 2 clinical trial of Eyecyte-RPE™, which focuses on Geographic Atrophy secondary to dry age-related macular degeneration.
Eyestem Research presented interim results from its Phase 2 clinical trial of Eyecyte-RPE™ for Geographic Atrophy secondary to dry age-related macular degeneration at the EURetina 2026 conference in Vienna, Austria.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.